Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of YKYY015 injection in adults with elevated LDL-C
CTR20254114Phase 2Active
- Sponsor
- Hangzhou Tianlong Pharmaceutical
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of YKYY015 in hypercholesterolemia, familial hypercholesterolemia (FH) and combined dyslipidaemia (2 arms), sponsored by Hangzhou Tianlong Pharmaceutical. Primary endpoints: Percent change from baseline in LDL-C, Abnormal laboratory tests, ECG, vital signs, and physical examination findings and 1 more. Started Dec 2025; status: active.
02
Drugs
YKYY015
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)combined dyslipidaemia
Beyond the preview
Go deeper on CTR20254114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254114.